PAK4 as a Potential Marker for Poor Response to Immunotherapy in Melanoma Patients - Biognosys

PAK4 as a Potential Marker for Poor Response to Immunotherapy in Melanoma Patients

Poster presented at ESMO 2022

 
Authors: Mitchell P. Levesque, Nigel Beaton, Kristina Beeler, Judy Kuo, Harry Nunns, Tobias Treiber, Julia Martinez Gomez, Jakob Vowinckel, and Anna Juncker-Jensen
Presenter: Mitchell P. Levesque (University of Zurich, Switzerland)

Date: September 10

Back to Resources overview

Helpdesk

Access our knowledge base with relevant resources and guiding information.

Contact

    Close banner

    SpectroDive™ 11

    Straightforward Validation
    of Your Protein Targets

    New: SpectroDive™ 11

    Straightforward Validation of Your Protein Targets

    learn more